The role of the Hippo pathway effector YAP1 in soft tissue sarcomas is poorly defined. Here we report that YAP1 activity is elevated in human embryonal rhabdomyosarcoma (ERMS). In mice, sustained YAP1 hyperactivity in activated, but not quiescent, satellite cells induces ERMS with high penetrance and short latency. Via its transcriptional program with TEAD1, YAP1 directly regulates several major hallmarks of ERMS. YAP1-TEAD1 upregulate pro-proliferative and oncogenic genes and maintain the ERMS differentiation block by interfering with MYOD1 and MEF2 pro-differentiation activities. Normalization of YAP1 expression reduces tumor burden in human ERMS xenografts and allows YAP1-driven ERMS to differentiate in situ. Collectively, our results identify YAP1 as a potent ERMS oncogenic driver and a promising target for differentiation therapy.
INTRODUCTION
Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children and adolescents, is subdivided into embryonal RMS (ERMS; z60%), alveolar RMS (ARMS; z20%), and other (z20%) subtypes (Belyea et al., 2012) . Most ARMS cases (z80%) are associated with the presence of a PAX3/7-FOXO1A fusion gene (ARMSp), which predicts clinical outcome and is sufficient to cause ARMS at low frequency in mice (Keller et al., 2004) . However, z20%
Significance
The molecular and cellular origins of ERMS are incompletely understood, and only a few ERMS-causing pathways have been identified in association with familial syndromes. Current therapies for RMS are aggressive, highly cytotoxic, and lead to life-altering sequelae for survivors. Over the past 30 years, little progress has been made in identifying more efficient and less aggressive regimens, which highlights the need for improved therapeutic approaches and a better understanding of the molecular changes underlying RMS formation and propagation. Here we identify YAP1 hyperactivity as a major molecular cause of ERMS, providing a rationale and mouse models for preclinical studies aimed at assessing the efficiency of YAP1 inhibition in combination with other regimens for differentiation therapy of ERMS.
of histologically diagnosed ARMS cases are negative for the expression of PAX3/7-FOXO1A fusion genes (ARMSn) and are indistinguishable from ERMS at the molecular level (Williamson et al., 2010) . In contrast to ARMS, the oncogenic drivers in ERMS and ARMSn are still incompletely defined. A hallmark of ERMS (and other RMS subtypes) is that the cells are locked in a proliferating myoblast state despite the expression of myogenic differentiation-regulating factors such as MYOD1 and Myogenin (Saab et al., 2011) . While the precise mechanism of differentiation inhibition is uncertain, it is believed that the relative abundance of MYOD1 activating or inhibiting E-protein heterodimer partners in RMS is shifted toward repressive heterodimers (Yang et al., 2009) . Overcoming the terminal differentiation block in RMS would open the door for differentiation therapy, which aims to halt tumor progression by forcing the cells to differentiate into nondividing muscle fibers (Al-Tahan et al., 2012; Saab et al., 2011) . However, our understanding of the mechanisms underlying this differentiation block in RMS remains insufficient to achieve better treatments.
The core Hippo pathway is regulated by many upstream signal transduction proteins in response to cues from the cellular microenvironment (Yu and Guan, 2013) . It generally functions to limit organ growth and tumorigenesis by inducing the cytosolic localization of the transcriptional cofactor YAP1, especially but not solely through Ser127 phosphorylation (Zhao et al., 2007) . Nuclear YAP1 promotes proliferation and inhibits apoptosis primarily by coactivating the TEAD family of transcription factors . Consistent with this, the constitutively active YAP1 S127A mutant is mostly nuclear (Zhao et al., 2007) and, with the exception of the intestine (Barry et al., 2013; Zhou et al., 2011) , promotes proliferation, expands undifferentiated stem cells and progenitors, and leads to tumor formation in epithelial tissues (Camargo et al., 2007; Dong et al., 2007; Schlegelmilch et al., 2011) . However, the role of YAP1 in soft tissue sarcomas is still poorly defined. In C2C12 myoblasts and cultured activated satellite cells (Judson et al., 2012; Watt et al., 2010) , YAP1 S127A drives proliferation and inhibits differentiation. Given that a pro-proliferation, antidifferentiation myoblast phenotype is the hallmark of RMS, here we tested whether YAP1 was involved in the development of rhabdomyosarcoma.
RESULTS

Increased YAP1 Copy Number and Elevated Expression in Human ERMS
To explore the role of YAP1 in human RMS, we first assessed the abundance and cellular localization of YAP1 protein in 78 ARMS and 196 ERMS samples. Representative YAP1 immunostainings are shown for human ERMS and ARMS tumors of each intensity category ( Figure 1A) . ERMS tumors expressed a significantly higher level of YAP1 protein than ARMS ( Figure 1B ) (p = 0.0046, Mann-Whitney U test). ARMS cases displayed a higher proportion of predominantly cytoplasmic staining (C), while ERMS cases displayed a greater proportion of nuclear (N) and dual nuclear/cytoplasmic staining (N/C). Indeed, there was a significant tendency for N/C expression to have a strong intensity score (chi-square test for trend, p = 0.0002), and YAP1 was more nuclear (N and N/C) in ERMS than ARMS ( Figure 1C ) (chi-square test, p < 0.0001, n = 227). We also found an association between the proliferation marker Ki67 and YAP1 staining within the ERMS subgroup, but not the ARMS ( Figure 1D ) (chi-square test for trend, p = 0.079, n = 184). Array CGH analysis from 79 human RMS samples (Williamson et al., 2010) revealed a significant increase in YAP1 locus copy number in ERMS and in fusion-negative RMS, which includes ERMS and fusion-negative ARMS (ARMSn), but not in fusion-positive ARMS (ARMSp) ( Figure 1E ) (Fisher's exact test, p = 0.012). These data demonstrate a higher YAP1 expression and activity in a high proportion of ERMS cases, but not ARMS, suggesting a causative role for YAP1 in ERMS development and/or propagation.
Expression of Activated YAP1 in Mouse Skeletal Muscle Causes ERMS
To test for a causal role of high YAP1 activity in RMS, we generated doxycycline-inducible (DOX-inducible) Myf5-hYAP1 S127A mice (Figure 2A ), in which DOX administration in adult mice induces the overexpression of the TetO-hYAP1 S127A transgene in the mature skeletal musculature, as well as in adult quiescent and activated satellite cells and their myoblast progeny (Beauchamp et al., 2000; Cornelison and Wold, 1997; Kuang et al., 2007; Tajbakhsh et al., 1996) . After 4-8 weeks of DOX administration, adult Myf5-hYAP1 S127A mice developed a rapidly progressing and severe gait defect with marked loss of limb flexibility (Figures S1A and S1B available online), which did not allow obvious tumors to form before euthanasia was required. Hematoxylin and eosin staining (H&E) revealed extensive muscle damage, loss of mature myofibers, and the presence of newly formed fibers with centrally located nuclei, indicative of ongoing muscle regeneration (Figures 2B and 2C, arrowheads) (Judson et al., 2013) . Additionally, a massive expansion of mononucleated cells was detected in the interstitial compartment of all muscles analyzed, including the tibialis anterior (TA) ( Figure 2B ), abdominal ( Figure 2C ), and gastrocnemius (GAS) muscles ( Figure 2D ).
Small well-demarcated tumor nodules located in the crural and/or hamstring muscles were macroscopically apparent at necropsy (Figures 2E and 2F ). These tumors expressed high levels of YAP1 ( Figure 2G ), Desmin ( Figure 2H ), Myogenin (Figure 2I) , and Caveolin-1 ( Figure 2J ) (Rossi et al., 2011) . Pathologists identified the interstitial expansion and primary tumors as non-alveolar RMS histologically similar to human embryonal RMS (ERMS) of the spindle cell variant accompanied by focal pleomorphic features. The brown fat pads, also derived from the MYF5 lineage (Seale et al., 2008) , appeared normal with no apparent myogenic differentiation or neoplastic lesions (Figures S1C and S1D). Dissociated cells (1 3 10 6 ) from the expanded interstitial compartment of DOX-induced Myf5-hYAP1 S127A mice produced tumors in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice with a latency ranging from 36 to 54 days ( Figure S1E ). These also resembled human ERMS ( Figure S1F ), expressed high levels of YAP1 ( Figure S1G ), Desmin (Figure S1H), and Myogenin ( Figure S1I ) and were transplantable ( Figure S1J ). Indeed, serial dilutions propagated the same type of secondary tumors with strikingly short latency and 100% penetrance after transplanting as few as 100 cells ( Figure S1K ).
High YAP1 Activity in the MYOD1 Lineage Induces ERMS To confirm that RMS can arise as a result of persistent YAP1 hyperactivity in activated satellite cells or myoblasts, we additionally generated Myod1-hYAP1 S127A mice ( Figure 2K ) (Kani-sicak et al., 2009) . Within 4 weeks of DOX treatment, Myod1-hYAP1 S127A mice developed a gait phenotype similar to Myf5-hYAP1 S127A mice, with obvious primary tumors in the limbs (Figures S1L and S1M) and in abdominal muscles at necropsy. H&E revealed signs of muscle damage, myofiber regeneration, and importantly, a widespread amplification of mononucleated cells in the interstitial compartment of the TA (Figures S1N and S1O) and abdominal muscles ( Figures 2L-2N) , along with the presence of centrally located nuclei in the remaining fibers ( Figure S1O , arrowheads). As in Myf5-hYAP1 S127A mice, cells in the amplified interstitial compartment expressed YAP1 ( Figure 2O ), Desmin ( Figure 2P ), and Myogenin ( Figure 2Q ). In addition, PCNA ( Figure 2R ), PAX7 ( Figure 2S ), MYOD1 ( Figure 2T ), and Caveolin-1 ( Figure 2U ) expression suggested extensive proliferation and a low degree of myogenic differentiation, compatible with an expansion of activated satellite cells and/or myoblasts. Dissociated primary tumor cells (0.5 3 10 6 ) propagated tumors in NOD/SCID ( Figure S1P ) with a similar histology as the secondary tumors from the Myf5-hYAP1 S127A model ( Figure S1Q ) and similar expression of YAP1 (Figure S1R), Desmin ( Figure S1S ), and Myogenin ( Figure S1T ). Collectively, these results reveal that MYF5 + and MYOD1 + activated satellite cells or myoblasts can be the cells of origin of YAP1-ERMS, which is further supported by the enhanced soft agar colony-forming potential of C2C12 myoblasts expressing hYAP1 S127A ( Figure S1U ).
High YAP1 Activity Does Not Induce Satellite Cells Activation but Transforms Activated Satellite Cells
Next we addressed the question of whether persistent YAP1 hyperactivity is sufficient to both activate and transform satellite cells. To overexpress hYAP1 S127A in quiescent and activated satellite cells, we generated DOX-inducible Pax7-hYAP1 S127A mice ( Figure 3A ) (Lepper and Fan, 2010) . DOX was given for 8 weeks, and muscle injury was induced via cardiotoxin (CTX) injection to the right hindlimb 3 weeks after the hYAP1 S127A induction in PAX7 + cells ( Figure 3B) . Surprisingly, the muscle morphology in the uninjured left hindlimb was unaffected after 8 weeks of DOX, and H&E staining showed no signs of expansion of the interstitial compartment ( Figure 3C ). Likewise, the percentage of satellite cells, assessed by the ratio of PAX7 + nuclei/total nuclei, remained unchanged (Figures S2A and S2B) . In contrast, the injured muscles of Pax7-hYAP1 S127A overexpressing mice displayed massive amplification of mononucleated cells 5 weeks after injury ( Figure 3D ), which was histologically consistent with RMS as determined by pathological examination. The core of the injured muscle expressed high levels of YAP1 ( Figure S2C Figure S2G ). We additionally introduced a ZsGreen1 reporter allele in Pax7-hYAP1 S127A mice in order to track the activated progeny of quiescent PAX7 + cells after CTX injury ( Figure 3E ). A longer DOX induction period after injury led to the development of ZsGreen1 + primary tumors at the injury site by using either CTX or a barium chloride injury method ( Figure 3F ). Sorted ZsGreen1 + cells from those primary tumors produced secondary ZsGreen1 + tumors expressing high levels of YAP1 ( Figure 3G ), Desmin ( Figure 3H ), and MYOD1 ( Figure 3I ), while PAX7 expression was overall low ( Figure 3J shows a representative patch of PAX7 + cells). Human ERMS tumors notably express PAX7 at variable levels (Tiffin et al., 2003) , and while viewed as indicative of a satellite cell origin, PAX7 expression is not a diagnostic criteria for RMS classification. Collectively, our results on three trans-genic mouse models (Myf5-, Myod1-, and Pax7-driven hYAP1 S127A expression) and two types of injury strongly suggest that persistent hyperactivity of YAP1 in activated but not quiescent satellite cells can potently cause ERMS-like tumors with remarkably short latency in mice.
Normalization of YAP1 Activity in YAP1-Driven ERMS Releases the YAP1-Imposed Differentiation Block In Situ
To test whether YAP1 reduction causes tumor regression, we withdrew DOX from host mice bearing secondary tumors following transplantation of sorted ZsGreen1 + Pax7-hYAP1 S127A primary tumor cells from the injury site ( Figure 4A , top panel). DOX-withdrawn tumors regressed to z 50% of their original size in 10 days ( Figure 4A , bottom panel) and coexpressed the myogenic differentiation marker sarcomeric myosin heavy chain (MyHC) and ZsGreen1 in myofibers at their core ( Figure 4B ). We observed a similar regression in Myf5-hYAP1 S127A allograft tumors 12 days after DOX withdrawal ( Figure 4C ). These tumors, after 6 days OFF DOX (OFF6) ( Figure 4D ), showed a marked decrease in the expression of YAP1 ( Figure 4E ), PCNA ( Figure 4F ), and Caveolin-1 ( Figure 4G ). Expression of Myogenin ( Figure 4H ) appeared unchanged, while Desmin immunostaining was suggestive of newly formed myofibers ( Figure 4I ). Consistently, Caveolin-3 ( Figure 4J ) and MyHC ( Figure 4K ) expression increased. Furthermore, coexpression of MyHC and ZsGreen1 ( Figure 4L ) at the core of the regressing tumors (Figures S3A and 3SB) confirmed the ability of the YAP1-ERMS tumor cells to differentiate into mature skeletal muscle in situ once YAP1 expression is normalized. In culture, ZsGreen1 + YAP1-ERMS cells from Myf5-hYAP1 S127A secondary tumors could be expanded in the presence of DOX ( Figure S3C ), but did not proliferate as well in its absence ( Figure S3D ). These cells also formed MyHC + and ZsGreen1 + double positive myotubes when plated at high density and subjected to differentiation conditions for 4 days in the absence of DOX ( Figure S3E ). These results suggest that persistent hYAP1 S127A hyperactivity causes ERMS-like tumors in mice both by promoting proliferation and imposing a differentiation block, which can be overcome once YAP1 activity is reduced.
Identification of YAP1 Target Genes in YAP1-ERMS
To characterize the mechanisms by which YAP1 drives ERMS, we aimed to identify the YAP1 target genes that could explain the sustained myoblast proliferation and differentiation-block phenotype of ERMS. We combined global gene expression analyses with chromatin immunoprecipitation-sequencing (ChIP-Seq) for the YAP1 cofactor TEAD1. YAP1 and TEAD1 mostly co-occupy the same promoters in MCF10A cells (>80% overlap) (Zhao et al., 2008) and directly interact in proliferating mouse myoblasts (Judson et al., 2012) . YAP1 does not bind DNA directly, so interaction with TEAD factors is responsible for most, if not all, of YAP's functions in vivo (Schlegelmilch et al., 2011) , and identification of YAP1 target genes is reliably associated with TEAD binding sites (Lian et al., 2010; Zhao et al., 2008) .
We first used microarray analysis to identify potential YAP1 target genes in the YAP1-ERMS tumors. We reasoned that YAP1 direct target genes would show a transcriptional response to reduction of transgenic YAP1 levels in regressing YAP1-ERMS after short-term DOX withdrawal for 3 and 6 days (OFF3, OFF6) ( Figure 5A ). We confirmed the decreased expression of the hYAP1 transgene and the YAP1 target gene Cyr61 by quantitative polymerase chain reaction (qPCR) ( Figure S4A ). The expression of satellite cell markers Pax7 and Myf5 also decreased in regressing tumors ( Figure S4A ). Myod1 and the terminal differentiation marker myosin heavy chain, Myh4, were upregulated during the regression compared to day 0 tumors ( Figure S4A ). Hierarchical clustering of microarray profiles showed a return of regressing tumors toward terminally differentiated muscle ( Figure 5B ), consistent with re-expression of myogenic differentiation markers in regressing tumors ( Figures 4J-4L ).
We next identified differentially expressed genes between YAP1-driven ERMS and each of the three conditions of low YAP1 activity: skeletal muscle control and DOX withdrawn for 3 days and 6 days. The overlap between the 3 lists identified a subset of 633 YAP1-upregulated genes ( Figure 5C ), as well as 249 YAP1-downregulated genes ( Figure 5D ). Within each list, 71% of the genes were also associated with TEAD1 occupancy in YAP1-ERMS cells ( Figure 5E and Table S1 ), suggesting that and contained mostly target genes of myogenic regulatory factors MYOD1, Myogenin, MEF2, and SRF ( Figure S4B) , suggesting a decreased activity of these factors when YAP1 activity is high. We next performed ChIP-qPCR validations for YAP1 ( Figure 5H ) and TEAD1 ( Figure 5I ) occupancy on a subset of peaks selected by the combination of microarray and ChIP-Seq analyses, confirming the correlation between TEAD1 binding peaks and YAP1 occupancy. Collectively, this suggests that YAP1-TEAD1 not only directly drives gene expression necessary for sustained proliferation but also contributes to blocking myogenic differentiation by repressing genes that are normally expressed in differentiated skeletal muscle. See also Figure S4 and Table S1 .
YAP1 Is Integrated in the Myogenic Differentiation Program and Represses Terminal Differentiation Genes
Studies since the late 1980s reported occurrence of TEAD DNA binding sites, named muscle CAT (MCAT) elements, in the promoters of genes that are selectively expressed in differentiated skeletal muscle (Yoshida, 2008) . Here we confirm and extend this observation genome-wide. Using motif enrichment analyses, we identified the overrepresentation of Myogenin, MEF2, or SRF consensus sequences within TEAD peaks or around the promoter of TEAD1-associated genes ( Figure S5A ). Nearly one-third (27%) of TEAD1 peaks in ''undifferentiated'' YAP1-ERMS cells are aligned with MYOD1, Myogenin, and/ or SRF binding peaks in differentiated C2C12 myotubes (Figure S5B ), suggesting that YAP1-TEAD1 globally regulates muscle lineage-specific gene expression in YAP1-ERMS. GO analysis of the shared TEAD1-MYOD1-Myogenin-SRF loci returned terms compatible with the YAP1-ERMS phenotype and with the role of YAP1 in the repression of the myogenic differentiation program ( Figures S5C and S5D) , while the TEAD1-only sites associated generally with immune processes and signaling pathways ( Figure S5E ). Among the genes harboring adjacent binding sites for TEAD1-MYOD1-Myogenin-SRF, a large number of repressed genes were associated with terminal muscle contraction and differentiation. The expression of these genes was reduced in YAP1driven ERMS but increased when YAP1 activity was lowered by DOX withdrawal ( Figure 6A ). Interestingly, MYOD1 and Myogenin binding occupancy increases during myogenic differentiation from myoblasts to myotubes, on loci shared with TEAD1 (Figure S5F ). This correlates with the concomitant decrease in YAP1 activity during myogenic differentiation (Judson et al., 2012; Watt et al., 2010) . We thus hypothesized that YAP1-TEAD1 occupancy could impinge on MYOD1 and MEF2 binding on shared sites associated with repressed muscle differentiation genes. To test this we evaluated the occupancy of MEF2 and MYOD1 on a selection of genes associated with myogenic differentiation or proliferation while altering the levels of YAP1 in cultured YAP1-ERMS cells via DOX withdrawal ( Figure 6B ). This analysis revealed that reduction of hYAP1 S127A expression, leading to differentiation of YAP1-ERMS cells, resulted in increased occupancy of MEF2 ( Figure 6C ) and/or MYOD1 ( Figure 6D ) specifically on myogenic differentiation genes, but not on proliferation-related genes. Such functional interplay between YAP1 and myogenic factors at shared loci cannot be explained by changes in MEF2 or MYOD1 expression levels as their expression did not increase during YAP1-ERMS differentiation ( Figure 6E ). However, both expression ( Figure 6E ) and occupancy of TEAD1 ( Figure 6F ) decreased during YAP1-ERMS cell differentiation on all genes tested, including proliferation-associated genes. Our data indicate that the sustained presence of YAP1-TEAD1 plays a role in repressing differentiation genes, partly by impinging on the differentiation promoting activities of myogenic transcription factors at muscle differentiation-associated loci.
YAP1 Upregulates Oncogenes and Inhibitors of Myogenic Regulatory Factors in Mouse YAP1-ERMS and Human ERMS Cells
Additionally, we observed upregulation of several canonical YAP1 target genes and RMS-related oncogenes (Figures 6G and S5D) in YAP1-ERMS, identifying YAP1 as a meta-oncogene and supporting the potency of YAP1 to trigger ERMS in mice. Among YAP1 upregulated genes, we identified a subset that encode known inhibitors of MYOD1 and MEF2 activity, including Id2, Twist1, Mdfic, Snai1, Snai2, and Cabin1 (Figure 6G) . Loci associated with the latter category of genes were also bound by YAP1 ( Figure 6H ) and TEAD1 ( Figure 6I ) in YAP1-ERMS cells and were upregulated at the protein level in induced muscle and YAP1-ERMS primary tumors from Myod1-hYAP1 S127A mice ( Figure 6J ). This suggests that YAP1 can block differentiation not only by affecting the occupancy of MYOD1 and MEF2 at myogenic differentiation-associated loci but also by upregulating the expression of inhibitors of myogenic transcription factors.
Interestingly, most YAP1-TEAD1 bound target genes validated in mouse YAP1-ERMS ( Figures 5H, 5I , 6H, and 6I) were also bound by YAP1 ( Figure S5G ) and TEAD1 ( Figure S5H ) in human ERMS RD cells, and some of these loci were also shared by MEF2 ( Figure S5I ) and MYOD1 ( Figure S5J ). In addition, gene expression analysis of the validated YAP1-TEAD1 target genes in RD cells ( Figure S5K ) and human ERMS ( Figure S5L) shows regulation similar to mouse YAP1-ERMS ( Figures 6A and 6G ), suggesting that the transcriptional program of YAP1 and its role in blocking differentiation is similar in human ERMS. Indeed, using the YAP1-ERMS signatures identified in mouse ( Figure 5E and Table S1 ), we could assess YAP1 activity in a microarray of human fetal myoblasts undergoing differentiation. Consistent with the impeding effect of YAP1 S127A on the differentiation of mouse myoblasts in vitro (Judson et al., 2012; Watt et al., 2010) , expression of YAP1 mRNA ( Figure S5M ) and the YAP1-ERMS-activated signature ( Figure S5N ) decreased progressively when human fetal myoblasts differentiated. Concurrently, expression of the YAP1-ERMS-repressed signature increased ( Figure S5O ). These data validate use of the YAP1-ERMS signatures as YAP1 activity readout in human cells and suggest that a decrease in YAP1 activity is also associated with myogenic differentiation in human myoblasts, as in mouse.
These analyses in YAP1-ERMS and human RD cells demonstrate that YAP1-TEAD1 binding is associated with three categories of direct target genes. YAP1-TEAD1 binding is associated first with expression of genes that promote proliferation and/or transformation, second, with repression of genes that are normally expressed in differentiated skeletal muscle, and third, with increased expression of MYOD1 and MEF2 inhibitors. Collectively, this suggests that persistent YAP1 hyperactivity not only drives proliferation and transformation, but also represses differentiated muscle lineage-specific genes, imposing a global differentiation block, which is a hallmark of RMS.
High YAP1 Activity Associates with Higher Stage in Fusion-Negative RMS and Trends with Poorer Prognosis
We next confirmed the importance of YAP1 activity in human RMS using two large series of human RMS primary tumors totaling 235 samples. First, YAP1 expression was higher in human ERMS and ARMSn compared to ARMSp ( Figure 7A ). YAP1 activity was next assessed using the YAP1-ERMSactivated and YAP1-ERMS-repressed signatures. YAP1 activity was high in all RMS subtypes compared to skeletal muscle (J) Western blot analysis for YAP1, MyHC, TEAD1, MEF2, and MYOD1 as well as genes involved in repression of MYOD1 activity (SNAI2, TWIST1, MDFIC) in control muscle (CTL), induced TA (TA), and primary tumors (TUM) from Myod1-hYAP1 S127A mice induced with DOX for 4 weeks. See also Figure S5. control, but also significantly elevated in ERMS and ARMSn over ARMSp (Figure 7B ), while the expression of the YAP1-ERMSrepressed signature was low in all subtypes ( Figure 7C) . The YAP1-ERMS-activated signature was significantly enriched in all RMS subtypes considered together versus skeletal muscle, along with the gene expression signatures of embryonic stem cells, Notch, and satellite cells activation ( Figure S6A and Table  S2 ). Remarkably, the YAP1-ERMS-activated signature was enriched specifically in ERMS versus ARMSp ( Figure S6B) , and more significantly than the satellite cells activation signature, which was previously reported as a hallmark of ERMS (Hatley et al., 2012; Rubin et al., 2011) . These results show that YAP1 activity is elevated in human ERMS and suggest that our YAP1-ERMS signatures could constitute a useful indicator of YAP1 activity in human RMS tumors as well.
Cancer Cell
We then investigated whether YAP1 activity is associated with prognosis and/or outcome in human RMS. Indeed, stage 3 and 4 tumors were significantly positively associated with higher YAP1 activity based on a multivariable linear regression model including clinicopathological features linked to RMS outcome (Table S3 and Figure 7D ), such as tumor histology, age, and tumor location. We next defined HIGH expression and LOW expression subgroups for both YAP1-ERMS signatures (activated and repressed) within each RMS subtypes and identified a trend (log rank test, p = 0.09) toward a poorer outcome for the subgroup with a higher expression score of the YAP1-ERMS-activated signature in fusion-negative, but not in fusion-positive, tumors ( Figure 7E) . Consistently, the reverse analysis using the YAP1-ERMSrepressed signature showed that the low expression subgroup associated with poorer outcome (log rank test, p = 0.05) in fusion-negative tumors, but not in fusion-positive tumors (Figure 7F) . Taken together, these results suggest that the YAP1-ERMS signatures can better segregate the fusion-negative RMS subtypes in terms of stage and outcome, possibly identifying tumors with higher proliferation rates and lower differentiation levels.
YAP1 Knockdown Decreases Proliferation and Tumorigenicity while Increasing Differentiation Capacity of Human ERMS
We next hypothesized that lowering YAP1 in human ERMS would release the terminal differentiation block. We stably introduced a DOX-inducible hYAP1 knockdown construct in RD cells (RD-TetO-shYAP1). DOX treatment of RD-TetO-shYAP1 cells for 5 days induced a marked reduction of YAP1 protein ( Figure 8A ) and mRNA levels ( Figure 8B) . Expression of the proliferation marker E2F1 ( Figure 8B ) and EdU incorporation also decreased ( Figure 8C ), while the number of MyHC + cells per myotubes increased, demonstrating an enhanced myogenic differentiation ( Figure 8D ). DOX-treated RD-TetO-shYAP1 cells cultured in soft agar formed fewer and smaller colonies ( Figures 8E and 8F) , suggesting that YAP1 knockdown additionally decreases tumorigenicity in vitro.
To assess the effects of YAP1 knockdown on ERMS tumorigenicity in vivo, we transplanted either control or hYAP1 knockdown RD cells into the gastrocnemius muscle of NOD/ SCID mice. Orthotopic xenografts from the hYAP1 knockdown RD cells were 42% smaller than tumors originating from control cells ( Figure 8G ). Efficient knockdown of YAP1 protein in the DOX-treated xenografts was confirmed by immunostaining for YAP1 ( Figure 8H) , which also correlated with decreased expression of human Ki67 ( Figure 8I ) and increased expression of MyHC ( Figures 8J and 8K) , indicating a greater degree of differentiation of tumors in the YAP1 knockdown condition. These results show that the tumorigenicity and low differentiation potential of ERMS can be rescued in vitro and in vivo by decreasing YAP1 expression, which functionally validates the potential benefits of YAP1 inhibition for differentiation therapy of ERMS. 
DISCUSSION
Here we show that YAP1 expression and activity are highest in human ERMS versus ARMS and find that many human ERMS, but not ARMS, harbor a copy number gain of the YAP1 locus. In addition, high YAP1 activity is associated with poorer prognosis in human ERMS cases, but not in ARMS. Consistent with this, we show that high YAP1 activity causes ERMS-like tumors in mice with surprisingly short latency and high penetrance compared to other mouse models of RMS, identifying YAP1 as an exceptionally potent ERMS oncogene.
Using Myf5-, Myod1-, and Pax7-driven Cre alleles in combination with muscle injury, we identify activated, but not quiescent, satellite cells as the cell of origin of YAP1-driven ERMS. Overexpressing a constitutively active hYAP1 S127A mutant in other tissues such as liver (Camargo et al., 2007; Dong et al., 2007) and skin (Schlegelmilch et al., 2011) increases the proliferation of progenitors and organ size without the need for a concomitant activating signal or injury. This might represent inherent differences in the basal cycling activity of these tissues. Indeed, adult skeletal muscle has a low cellular turnover (Spalding et al., 2005) as satellite cells are normally mitotically quiescent and only rarely become activated to fulfill the sporadic demands for hypertrophy or repair. Intriguingly, this partly mirrors human pathogenesis as ERMS generally occurs in children and adolescents, where postnatal muscle growth is dependent on satellite cell activity (Parham and Ellison, 2006) . Additionally, dystrophic mice, in which a large fraction of satellite cells is activated (Pallafacchina et al., 2010) , spontaneously form RMS (Chamberlain et al., 2007; Hosur et al., 2012) , and further studies are required to establish the role of aberrant YAP1 activity in muscular dystrophies and their associated RMS.
Although insufficient to activate quiescent satellite cells under homeostatic conditions in adult mice, YAP1 is sufficient to drive RMS from activated satellite cells by maintaining the myoblast state in a global manner. Indeed, YAP1 not only promotes persistent proliferation of activated satellite cells but also arguably acts as a meta-oncogene by promoting the expression of a number of oncogenes associated with RMS (Myc, Met, Rras2, Maff, Birc5/ Survivin). In parallel, YAP1 also imposes a differentiation block in a direct and indirect manner via its transcriptional program.
First, YAP1-TEAD1 bind to the promoters of genes normally expressed only in terminally differentiated muscle and appear to repress the activity of myogenic factors by impinging on the recruitment of MYOD1 and MEF2 on myogenic differentiationassociated loci. While it was known since the late 1980s that a few differentiated skeletal muscle genes contain TEAD-targeted MCAT elements (Yoshida, 2008) , our study demonstrates that YAP1-TEAD1 operate genome-wide to regulate lineage-specific gene expression in skeletal muscle. The repressive effect of YAP1-TEAD1 binding specifically on myogenic differentiationassociated loci also suggests that YAP1 is not only acting as a co-activator for the TEAD family of transcription factors. The transcriptional outcome of YAP1-TEAD1 binding most likely depends on the general chromatin context. Indeed, a repressive role of YAP1-TEAD1 was only reported recently in ES cells (Beyer et al., 2013) , and taken together with our results, this supports the concept that YAP1-TEAD1 can be integrated into larger repressive complexes in a context-and lineage-specific manner.
The notion that YAP1 can act with the same partner in multiple transcriptional mechanisms is intriguing, although in agreement with the different effects of YAP1 overexpression across various tissues (Barry et al., 2013; Camargo et al., 2007; Schlegelmilch et al., 2011) .
Second, YAP1 also blocks the myogenic differentiation program in an indirect manner by upregulating the expression of known repressors of MYOD1 pro-differentiation activity (Twist1, Mdfic, Snai1, and Snai2) . This is consistent with the idea that myogenic factors are expressed but inactive at completing the differentiation program in RMS and that the balance between MYOD1 activating or repressing heterodimers is shifted toward repression in RMS (Yang et al., 2009) . Twist1 is a known repressive heterodimer partner of MYOD1 (Yang et al., 2009) and was previously reported to play a role in RMS development (Maestro et al., 1999) . CABIN1 and MASTR are coregulators of MEF2 factors (Creemers et al., 2006; Jang et al., 2007; Meadows et al., 2008; Mokalled et al., 2012) , and SNAI1 and SNAI2 were recently reported to direct MYOD1 away from its pro-differentiation targets genes in proliferating myoblasts (Soleimani et al., 2012) . Thus, under high YAP1 activity, upregulation of TWIST1 and SNAI1 and SNAI2 expression by YAP1-TEAD1 likely adds another repressive layer for MYOD1 transcriptional activity on differentiation genes. Our study clearly demonstrates that the transcriptional program of YAP1-TEAD1 in ERMS can globally sustain the myoblast phenotype by acting simultaneously on several interlinked cellular functions including proliferation, transformation and terminal differentiation.
In addition, our study identifies YAP1 inhibition as a promising strategy for differentiation therapy of ERMS. Despite the recent report that the Hippo pathway, via its upstream regulator RASSF4, was involved in fusion-positive alveolar RMS (Crose et al., 2014) , a direct link between ARMS development and YAP1 was not conclusively demonstrated. Our results might suggest a higher importance of YAP1 in ERMS development and propagation. Indeed, higher stage ERMS, which usually require more aggressive therapies, display elevated YAP1 activity and are associated with poorer prognosis, while the fusion positive tumors displaying high or low YAP1 activity appear equally aggressive. Reducing YAP1 activity in YAP1-ERMS tumors as well as in human ERMS RD cells was sufficient to decrease their proliferation and transformed state and resulted in myogenic differentiation. Importantly, we confirmed that differentiation therapy through YAP1 inhibition is effective not only in YAP1-driven mouse ERMS but also in more complex human ERMS tumors via orthotopic xenograft assays. Our results collectively support that YAP1 inhibition should be explored in preclinical studies as a differentiation therapy approach to restore differentiation of fusion-negative RMS in cooperation with other therapeutic modalities.
EXPERIMENTAL PROCEDURES
Mouse Strains, Animal Procedures, and Human Samples
The Pax7-cre/ERT2 (stock 012476), Myf5-Cre (stock 007893), Myod1-iCre (stock 014140), ZsGreen1 reporter (stock 007906), and NOD/SCID (stock 001303) mice were purchased from the Jackson Laboratory. The R26-Stop-rtTA and Col1a-TetO-hYAP1 S127A mice were previously described (Schlegelmilch et al., 2011). The Pax7-creERT2 mice were treated with tamoxifen (Sigma) solubilized in corn oil (Sigma) and administered as previously described (Lepper and Fan, 2010) . Doxycycline hyclate (Sigma) was administered in drinking water. Cardiotoxin from Naja naja mossambica (4.5 mM) (Sigma) was injected intra-muscularly 24 hr prior to transplantation (25 ml). All procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Boston Children's Hospital and Joslin Diabetes Center Institutional Animal Care and Use Committee. The human RMS sample collection from UK centers through the Children's Cancer and Leukemia Group was performed under the Local Research Ethics Committee protocol Nos. 1836 and 2015 and Multi-Regional Research Ethics Committee/06/4/71, with consent, as previously described (Tonelli et al., 2012; Wachtel et al., 2006) .
Primary Cells Preparation, Stable Cell Line Generation, and Xenograft Assay
For transplantation in NOD/SCID hosts, muscle interstitial cells from DOXinduced donor mice (8 weeks induction) were prepared from a two-digest protocol as previously described (Sherwood et al., 2004) . The tumors were dissociated using the same protocol except that a single combined digestion step was performed for 60-75 min at 37 degree. Cells were either transplanted into NOD/SCID hosts directly or sorted for expression of ZsGreen1 by flow cytometry as indicated. Sorted tumor cells were transplanted or cultured (Dulbecco's modified Eagle's medium supplemented with 20% fetal bovine serum, pen and strep, glutamine) in the presence of DOX (2 mg/mL). RD cells were infected with an inducible YAP1-TRIPz-TetO-shRNA lentivirus (Open Biosystems) expressing red fluorescent protein (RFP) and a short hairpin targeting YAP1 upon DOX induction. Cells were selected with puromycin for 5 days, then DOX was added for an additional 4 days before RFP positive cells were sorted by flow cytometry. Sorted RD-TetO-shYAP1 cells were cultured for 4 days in the presence or absence of DOX, and then 4.4 million cells were transplanted into the GAS of injured NOD/SCID recipients.
Human RMS Tissue Microarray and Gene Expression Analysis
The human RMS tissue microarray construction and human samples collection were previously described (Tonelli et al., 2012; Wachtel et al., 2006) . The gene expression profile of 235 RMS patients from two publicly available data sets were analyzed: one containing 101 samples [Innovative Therapies for Children with Cancer/Carte d'Identité des Tumeurs (ITCC/CIT)] (Williamson et al., 2010 ) and a second with 134 samples [Children's Oncology Group/Intergroup Rhabdomyosarcoma Study Group (COG/IRSG)] (Davicioni et al., 2009) . Raw data for the COG/IRSG collection was obtained from the NCI Cancer Array Database and from Prof. M.J. Anderson. Raw data for the ITCC/CIT collection are in ArrayExpress (E-TABM-1202). The two data sets were normalized separately using a robust multiarray average. Gene expression profiles of normal skeletal muscles and other relevant controls were obtained from public resources; details are reported in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
Microarray and ChIP-Seq data are deposited in the Gene Expression Omnibus database (GSE47198 and GSE55186, respectively).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, six figures, and three tables and can be found with this article online at http://dx.doi.org/10.1016/j.ccr.2014.05.029.
